Oncolytics Biotech, Inc.

Twitter LinkedIn
  • Home
  • About
    • Our Company
    • Management Team
    • Board of Directors
  • Technology
    • What is Pelareorep?
    • What Does Pelareorep Do?
    • Delivery
    • Intellectual Property
    • Posters & Publications
    • Manufacturing
  • Clinical Trials
    • Clinical Development Plan
    • Collaborators
    • Pipeline
  • Media
    • Press Releases
    • Insights
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • FAQs
    • Email Alerts
    • IR Contacts
  • Contact
  • Careers

News

Media

Media

  • Press Releases
  • Insights
Nov 2, 2017

Oncolytics Biotech® Appoints Deborah Brown to Board of Directors

Oct 11, 2017

Oncolytics Biotech® to Present at the 2017 BIO Investor Forum

Sep 19, 2017

Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference

Sep 18, 2017

Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer

Sep 14, 2017

Oncolytics Biotech® Announces First Patient Treated in MUK eleven Study

Sep 11, 2017

Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 Congress

Aug 3, 2017

Oncolytics Biotech® Inc. Announces 2017 Second Quarter Results

Aug 1, 2017

Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference

Jul 26, 2017

Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress

Jun 29, 2017

Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc.

    • 1...
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • ...53
    © 2021 Oncolytics Biotech, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap